• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Exosens (ENXTPA:EXENS) Plans To Triple Camera Capacity, Is It Still 15% Below Fair Value?

    Simply Wall St·08/01/2026 03:31:08
    Listen to the news

    Exosens (ENXTPA:EXENS) is back in focus after announcing plans to triple thermal camera production capacity in 2026, alongside half year 2026 results and a reiteration of full year revenue and EBITDA guidance.

    See our latest analysis for Exosens.

    Despite Exosens confirming guidance and outlining sizable capacity increases for thermal and cooled infrared cameras, the stock has had a mixed run. The 1-year total shareholder return of 38.8% contrasts with a year to date share price return of 14.4% and a 90 day share price decline of 11.8% from the current €57.2 level, suggesting recent caution after a stronger longer term performance.

    If growth in advanced imaging and defense tech interests you, it can be useful to see what else is on the move. Take a look at 35 power grid technology and infrastructure stocks

    Bulls point to Exosens' capacity build out and revenue guidance near the top of its range. Bears focus on the recent share pullback and softer half year net income. Which side does the current valuation support?

    Most Popular Narrative: 14.8% Undervalued

    The most followed narrative values Exosens at €67.13 per share, above the current €57.2 price, and frames that gap through growth and defense demand assumptions.

    The significant increases in global defense spending, especially the raised NATO target to 3.5% of GDP, combined with Exosens' leadership in night-vision and amplification technologies, position the company to benefit from a multi-year surge in demand for high-end defense sensing equipment, which is likely to drive sustained high revenue growth and improved order visibility.

    Read the complete narrative.

    Want to see what sits behind that valuation gap for Exosens. The narrative leans on compounded revenue growth, rising margins, and a richer earnings multiple, all carefully modeled but not yet fully unpacked here.

    Result: Fair Value of €67.13 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, Exosens still faces execution risk if capacity expansion runs into supply bottlenecks, and lower margin acquisitions could drag on group profitability if integration disappoints.

    Find out about the key risks to this Exosens narrative.

    Another View On Exosens Valuation

    The fair value of €67.13 comes from growth and cash flow assumptions, yet Exosens currently trades on a P/E of 51.9x versus a fair ratio of 28.5x and a peer average of 31.1x. That is a rich premium. Does this point to upside, or to more valuation risk if sentiment cools?

    See what the numbers say about this price — find out in our valuation breakdown.

    ENXTPA:EXENS P/E Ratio as at Aug 2026
    ENXTPA:EXENS P/E Ratio as at Aug 2026

    Next Steps

    With sentiment clearly split on Exosens, this is a good moment to move fast, review the data, and decide where you stand. To see what optimism is building around the company, start with the 3 key rewards

    Looking For More Investment Ideas Beyond Exosens?

    If you only stop at Exosens, you risk missing other stocks that could fit your goals just as well. Use the Simply Wall Street Screener to quickly surface fresh ideas tailored to how you like to invest.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.